Clinical trial matching.

Slides:

Advertisements

Similar presentations

BRIDG Overview Clinical Observation Interoperability March 18, 2008.

Advertisements

Cancer Treatment from the DNA Perspective

Clinical Trials Hanyan Yang

Cancer Program Standards 2012: Ensuring Patient- Centered Care Commission on Cancer.

Azara Proprietary & Confidential Overview June 2014 Improving Patient Outcomes through Data.

Comorbidity in SLE Compared with Rheumatoid Arthritis and Non-inflammatory Disorders Frederick Wolfe 1, Kaleb Michaud 1,2, Tracy Li 3, Robert S. Katz 4.

Prostate Cancer Research in Europe European Union Prostate Cancer Research Framework Program (FP) 6 FP6 funded projects in fiscal years 2004/2005 Total.

Suppl Fig. 1a The clinical protocol is shown schematically.

Agency Review of sNDA SE-006 DOXIL for Ovarian Cancer Division of Oncology Drug Products Office of Drug Evaluation 1 Center for Drug Evaluation.

NCI Clinical Trials Reporting Program CTRP User Meeting June 6, 2012 Gene Kraus CTRP Program Director.

INTERPRETING GENETIC MUTATIONAL DATA FOR CLINICAL ONCOLOGY Ben Ho Park, M.D., Ph.D. Associate Professor of Oncology Johns Hopkins University May 2014.

10th International Biocuration Meeting

Copyright © 2004 American Medical Association. All rights reserved.

Accelerating Precision Medicine for Advanced Cancer Patients

Randomized Trials: A Brief Overview

Verstovsek S et al. Proc ASH 2011;Abstract 793.

Pharmacogenetic effects on pharmacokinetics and pharmacodynamics

The cBio Cancer Genomics Portal.

Summary of genetic alterations in resistant biopsies among patients progressing on ceritinib or alectinib. Summary of genetic alterations in resistant.

Assessing Copy Number Alterations in Targeted, Amplicon-Based Next-Generation Sequencing Data Catherine Grasso, Timothy Butler, Katherine Rhodes, Michael.

The Genomics of Cancer and Molecular Testing:

Landscape overview of GENIE dataset.

Ewing sarcoma tumors acquire somatic aberrancies with treatment.

West of England Genomics Medicine Centre Overview

Clinical Observation Interoperability March 18, 2008

Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal- Finding Clinical Trial Chih-Jian Lih, Robin D. Harrington, David.

WES detects a limited number of clinically targetable alterations in patients with advanced cancer. WES detects a limited number of clinically targetable.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

European Urology Oncology

Volume 72, Issue 4, Pages (October 2017)

Genomic alterations in breast cancer cell line MDA-MB-231.

Genomic alterations in non–small cell lung cancer, breast cancer, and colorectal cancer. Genomic alterations in non–small cell lung cancer, breast cancer,

Volume 27, Issue 3, Pages (March 2015)

Mutational burden of somatic, protein-altering mutations per subject from WES for patients with advanced colon cancer who participated in PD-1 blockade.

Potential clinical actionability.

AACR Project GENIE at a glance.

Patterns of Somatically Acquired Amplifications and Deletions in Apparently Normal Tissues of Ovarian Cancer Patients Leila Aghili, Jasmine Foo, James.

Whole-exome sequencing identifies NF1 mutations in tumors of melanoma patients exhibiting resistance to vemurafenib. Whole-exome sequencing identifies.

Volume 9, Issue 3, Pages (March 2006)

Genetic landscape of salivary duct carcinoma.

Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal- Finding Clinical Trial Chih-Jian Lih, Robin D. Harrington, David.

A New Approach to Clinical Trials

Volume 29, Issue 5, Pages (May 2016)

Patterns of Somatically Acquired Amplifications and Deletions in Apparently Normal Tissues of Ovarian Cancer Patients Leila Aghili, Jasmine Foo, James.

Study design and comparison of study groups across time.

Cancer mutations in enriched RBP motifs.

Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.

Fig. 2 Estimate of the neoantigen repertoire in human cancer.

Identifying TRK Fusions in Head and Neck Cancer

Personalized genomic analyses for cancer mutation discovery and interpretation by Siân Jones, Valsamo Anagnostou, Karli Lytle, Sonya Parpart-Li, Monica.

Study overview. Study overview. A, Schematic illustrating clinical trial design and the nature and number of tissue specimens available for downstream.

Overview of TIMER modules on the website.

EN1 expression in breast cancer and clinical outcome.

Association between BRCA1 transcript level and cisplatin sensitivity, BRCA1 promoter methylation, and NtAI. Association between BRCA1 transcript level.

MPM cases with GNH. A, WES-based LOH profiling with the FACETS algorithm revealed three MPM samples with genome-wide LOH. B, Allelic copy-number plots.

The long tail of mutational hotspots in cancer.

Location of the ER mutations and frequencies per cohort.

Ten most frequent TCRs in the bulk 12TILs comprise >99% of the TIL population, and the neoantigens are shown to be the most dominant clones. Ten most frequent.

Frequently mutated genes in colorectal cancer.

Global mutational landscape of the 170 lung adenocarcinoma patients (discovery cohort). Global mutational landscape of the 170 lung adenocarcinoma patients.

Concordance between the genomic landscape identified by whole-exome sequencing of plasma cfDNA and tumor; DNA and recurrence of KDR/VEGFR2 oncogenic mutations.

Strategies for personalized precision immunotherapy.

Landscape of genomic alterations identified by WES in biopsies of patients with advanced PDAC. Co-mutation plot displaying integrated genomic data for.

PIK3CA somatic mutation and amplification frequency in prostate cancer

Mutational signature analysis of WES data from patients with advanced PDAC. A, Projection of signatures representing four main mutational processes identified.

Detection of BRCA reversion mutations in pretreatment cfDNA and tumor biopsy. Detection of BRCA reversion mutations in pretreatment cfDNA and tumor biopsy.

High genomic fidelity of SCLC PDX models derived from both CTCs and biopsies. High genomic fidelity of SCLC PDX models derived from both CTCs and biopsies.

Driver pathways and key genes in OSCC

Integrated analysis of gene expression and copy number alterations.

Molecular characterization of esophagogastric tumors.

Presentation transcript:

Clinical trial matching. Clinical trial matching. Overview of GENIE samples matched to NCI-MATCH, based on genomic and cancer type criteria. Each patient with a reported sequencing date in 2014 or later was matched against 18 arms of the study that use somatic mutations or copy-number alterations for enrollment. Arms with fusion criteria were excluded because only two of the eight contributing GENIE centers provided fusion data. A, Information regarding 18 arms of the NCI-MATCH trial, including a summary of genomic trial eligibility, and the total count of GENIE samples matched. For arms S1 and U (indicated with an asterisk), the exact set of inactivating mutations was not specified in the NCI protocol, and all mutations were therefore considered matches. B, Proportion of the matches attributed to the top 10 most frequently matched cancer types. The categories are the top-level OncoTree codes. C, Comparison of the observed matching rate in the GENIE cohort with the reported rates observed by the first 645 patients by the NCI-MATCH group. Substudies X and Z1D had not reported interim rates. The AACR Project GENIE Consortium Cancer Discov 2017;7:818-831 ©2017 by American Association for Cancer Research